RJV001 Study in Adults Receiving Abdominoplasty
Summary
In this study, we are testing a new drug against submental fat (SMF), which is characterized with the accumulation of fat under the chin that often appears as a "double chin". The 2018 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures indicated that 73% of respondents were bothered by "excess fat under the chin/neck". This condition of loose or sagging skin under the chin may affect facial symmetry and attractiveness, which can lead to social embarrassment and a negative self-image in many patients. There is an insufficiency in effective drugs against SMF and double chin. Although an injectable small molecule can be used for improvement of double chin, but its side effects are evident and its cost is high. As such, there remains a real need to develop a cost-effective method to improve appearance of SMF and double chin.
Timeline
- Start
- 2021-04-16
- Primary completion
- 2021-12-16
- Completion
- 2021-12-16
Publications
- Results Asds consumer survey on cosmetic dermatologic procedures: American Society for Dermatological Surgery; 2018. (Available from: https://www.asds.net/Portals/0/PDF/consumer-survey-2018-infographic.pdf.)
- Results Schlessinger J, Weiss SR, Jewell M, Narurkar V, Weinkle S, Gold MH, Bazerkanian E. Perceptions and practices in submental fat treatment: a survey of physicians and patients. Skinmed. 2013 Jan-Feb;11(1):27-31.
- Results Mukherjee A. Pharmacology review(s) of xiaflex. 2009.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RJV001 | Protein / enzyme biologic | 0.04 mg | Subcutaneous |
| Subject | RJV001 | Protein / enzyme biologic | 0.075 mg | Subcutaneous |
| Subject | RJV001 | Protein / enzyme biologic | 0.15 mg | Subcutaneous |
Indications
No indication recorded.